).
• Results: Improvements in weekly UUI episodes were similar for the 790 women who received extended-release formulations of oxybutynin (n=391) or tolterodine (n=399). Oxybutynin was significantly more effective than tolterodine in reducing micturition frequency (P=.003), and 23.0% of women taking oxybutynin reported no episodes of urinary incontinence compared with 16.8% of CNS = central nervous system; FDA = Food and Drug Administration; OAB = overactive bladder; OBJECT = Overactive Bladder: Judging Effective Control and Treatment; OPERA = Overactive bladder: Performance of Extended Release Agents; UUI = urge urinary incontinence women taking tolterodine (P=.03). Dry mouth, usually mild, was more common with oxybutynin (P=.02). Adverse events were generally mild and occurred at low rates, with both groups having similar discontinuation of treatment due to adverse events.
• Conclusions: Reductions in weekly UUI and total incontinence episodes were similar with extended-release formulations of oxybutynin and tolterodine. In the oxybutynin group, micturition frequency was significantly lower, and the percentage of women reporting no urinary incontinence episodes was significantly higher compared with the tolterodine group. Dry mouth was more common with oxybutynin, but tolerability was otherwise comparable, including adverse events involving the central nervous system.
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O veractive bladder (OAB) is a common condition characterized by symptoms of urgency (a strong desire to urinate) and frequent micturitions with or without urge urinary incontinence (UUI) (involuntary loss of urine). It affects almost 17 million people in the United States. 1 The economic cost of incontinence in the United States is high, with estimates in 1995 of $16.3 billion 2 and $26.3 billion. 3 For editorial comment, see page 681.
Results from the standard Short Form 36-Item Quality of Life Questionnaire have shown that individuals with OAB have a lower quality of life in the social and functional domains than those with diabetes. 1 Urge urinary incontinence has been associated with multiple nighttime awakenings and increased skin infections requiring treatment. 4 Additionally, women with weekly UUI have a 26% greater risk of sustaining a fall and a 34% increased risk of fracture after adjustment for other causes (eg, age, frailty, poor overall health, and previous fall or fracture). 4 Zorn et al 5 found that depression occurred in 60% of study participants with idiopathic UUI compared with 14% of those with stress incontinence. Finally, Melville et al 6 found major depression in 21% of study participants with UUI compared with 3% of those with stress incontinence. Herzog and Fultz 7 found that incontinence is often medically unrecognized and that only one quarter to one half of individuals with the disorder seek medical attention. Many individuals with OAB do not seek help if they perceive UUI to be an inevitable outcome of advancing age. Furthermore, of those who seek help, approximately 80% do not receive treatment. 1 Behavioral therapy, one approach to the management of OAB, can be highly effective in clinical trials, 8 but noncompliance outside such settings has the potential to limit its long-term efficacy. 1 The use of anticholinergic agents has been the mainstay of pharmacological treatment, but the inconvenience of taking multiple daily doses, adverse effects, and dissatisfaction with treatment have limited the long-term use of these immediate-release medications. 1, 9 An extended-release formulation of oxybutynin chloride was approved by the Food and Drug Administration (FDA) in December 1998, and a long-acting form of tolterodine tartrate was FDA-approved in December 2000. 10, 11 These formulations offer the convenience of oncea-day dosing. In addition, they reduce the peak concentration that occurs with each dose, decrease the number of peaks associated with multiple doses of the immediate-release formulations, and mitigate the peak-to-trough variation associated with the immediate-release formulations. 10, 12 Indeed, studies comparing extended-and immediate-release formulations of oxybutynin and tolterodine have reported better therapeutic windows with extended-release formulations. 13, 14 Before extended-release tolterodine was FDA-approved, Appell et al 15 compared 10 mg of once-daily extended-release oxybutynin to 2 mg of twice-daily immediate-release tolterodine, the only formulation available at the time of the OBJECT (Overactive Bladder: Judging Effective Control and Treatment) study. They reported that extendedrelease oxybutynin was superior to immediate-release tolterodine for reducing UUI episodes, total incontinence episodes, and micturition frequency. Both study groups had similar degrees of dry mouth and other adverse events.
With the subsequent introduction of extended-release tolterodine, long-acting formulations have been prescribed increasingly to treat OAB. This study, designated OPERA (Overactive bladder: Performance of Extended Release Agents), was designed to be the first direct comparison of extended-release formulations of oxybutynin and tolterodine.
PATIENTS AND METHODS Objectives
The primary objective of the OPERA study, conducted at 71 US study centers, was to compare the efficacy of extended-release formulations of oxybutynin and tolterodine in reducing UUI episodes during a 12-week treatment period in women with OAB. The secondary objective was to compare the tolerability of the 2 treatments.
Participants
Women with OAB, aged 18 years and older, who documented 21 to 60 UUI episodes per week and an average of 10 or more voids per 24 hours were recruited for this study. They were eligible if they had more urge than nonurge incontinence episodes. Participants could be enrolled whether or not they had a history of prior treatment with an anticholinergic drug for OAB; they were not queried regarding which drug, if any, they had taken. Those taking antihypertensive medications had to be taking a stable dose for at least 90 days before entering the study, with no plans to change the medication or dose.
Exclusion criteria included the following: treatable genitourinary conditions that could cause incontinence, 2 postvoid residual urine volumes shown by ultrasonography to exceed 150 mL, pronounced risk of developing complete urinary retention, clinically important medical problems that would put a participant at undue risk of anticholinergic effects, hematuria, uncontrolled narrow-angle glaucoma, obstructive uropathy, reduced gastrointestinal motility, and known hypersensitivity to the study medications.
Intervention
Participants with satisfactory results on physical examination and baseline laboratory testing were randomly assigned (1:1) to take either extended-release oxybutynin at 10 mg/d or extended-release tolterodine at 4 mg/d. Overencapsulation of the study medications ensured that both participants and investigators were blinded to the assigned treatment. Participants were instructed to take a single capsule at or about 8 AM daily for 12 weeks from November 21, 2000 , to October 18, 2001 .
The procedures of this study complied with the guidelines of the Declaration of Helsinki on biomedical research involving human subjects and were in accordance with the International Conference on Harmonisation and Guideline for Good Clinical Practice. The appropriate institutional review board of each participating center reviewed and approved the protocol and consent forms. Each study participant signed an institutional review board-appointed consent form.
Efficacy Assessments
Efficacy assessments were based on data kept in seven 24-hour urinary diaries at the baseline week and during weeks 2, 4, 8, and 12 of treatment. Weekly totals of UUI episodes, total incontinence (defined as urge plus nonurge incontinence) episodes, and micturition frequency during 7 consecutive days at baseline and during weeks 2, 4, 8, and 12 were recorded.
Statistical Analyses
All efficacy analyses were based on an intent-to-treat population defined as all participants who took a study drug and completed at least 1 efficacy assessment while receiving treatment.
The planned primary analysis was a comparison of the mean final weekly UUI episodes between treatment groups based on an analysis of covariance model with treatment as the factor and baseline value as a covariate. Additional planned analyses included comparison of the weekly total incontinence episodes and the weekly micturition frequency with use of an analysis of covariance. The percentage of participants with no UUI episodes and percentage of participants with no incontinence episodes in each treatment group was compared by using a χ 2 test. Efficacy data were also evaluated at each assessment time: week 2, week 4, week 8, and week 12 (week-12 analyses represent results from participants who completed 12 weeks of therapy).
Median percent reductions from baseline in incontinence and micturition frequencies were also compared between the 2 treatment groups by using the Wilcoxon rank sum test because of the nonnormal distribution of the outcome data.
14 The Cochran-Mantel-Haenszel method was used to compare percentages of patients in the 2 treatment groups who reported dry mouth.
Assessments of Safety and Tolerability
Adverse events data were collected at each visit or at any other time when reported by a participant. Investigators rated severity of adverse events by using the following definitions.
Mild-Event is noticeable but does not influence daily activities and usually would not need intervention.
Moderate-Event may be sufficiently troublesome to make the person uncomfortable, may influence performance of daily activities, and may need intervention.
Severe-Event may cause severe discomfort, usually interferes with daily activities, usually needs treatment or intervention, and may cause the person to discontinue the study.
RESULTS

Demographics
A total of 790 women were enrolled at 71 US centers; 391 were assigned to extended-release oxybutynin and 399 to extended-release tolterodine. Demographic characteristics as well as baseline averages of weekly episodes of UUI, weekly total incontinence episodes, and weekly micturition frequency were similar between both groups (Tables 1 and 2 ). Of the total number of participants, 61% were 64 years of age or younger, 24.5% were 65 to 74 years old, and 15% were 75 years of age or older; 53% had not previously used anticholinergic drugs for OAB.
Participation and Dropouts
A total of 339 participants (87%) in the extended-release oxybutynin group and 357 (89%) of those in the extended-release tolterodine group completed 12 weeks of treatment. Adverse events were the most common reason for discontinuation. Although more participants in the oxybutynin vs tolterodine group were lost to followup, at last observation they had better mean responses on all measures and fewer adverse events for the number of dropouts; thus, it does not appear that efficacy or tolerability determined the difference between groups. Participation and reasons for discontinuation are summarized in Figure 1 .
Efficacy
There was no statistical difference in the number of final average weekly UUI episodes (primary end point) between the 2 groups. The mean weekly episodes of UUI decreased from 37.1 recorded at baseline to 10.8 (last observation carried forward) for the oxybutynin group and from 36.7 recorded at baseline to 11.2 (last observation carried forward) for the tolterodine group. The decrease from baseline in the mean number of total incontinence episodes at the last observation was greater for those taking oxybutynin (from 43.4 to 12.3) than for those taking tolterodine (from 42.4 to 13.8), but this difference was not statistically significant. Oxybutynin participants had a greater decrease in the mean weekly micturition frequency compared with tolterodine participants (28.4 vs 25.2, respectively, compared to means of 66.4 and 71.1, respectively; P=.003).
The proportion of participants who reported total dryness (no incontinence episodes) in their last 7-day 24-hour voiding diary was 23.0% for those taking oxybutynin vs 16.8% for those taking tolterodine (P=.03). The proportion of participants who reported no UUI episodes at the last assessment was 26.7% for those taking oxybutynin vs 20.9% for those taking tolterodine (P=.06).
When results for UUI episodes (Figure 2 ), total incontinence episodes (Figure 3 ), micturition frequency ( Figure  4 ), and percent with no incontinence episodes ( Figure 5 ) were analyzed at each efficacy assessment, oxybutynin participants consistently had numerically superior results and also had statistically significantly greater results than tolterodine participants at approximately half the assessment points.
The median percentage reductions in UUI, total incontinence, and micturition frequency were analyzed at the final visit and at each assessment point. The Wilcoxon rank sum test was used because the percentage reductions were not normally distributed. Results at each assessment point and at the final visit revealed greater reductions in the oxybutynin group, many of which were statistically significant or represented a trend (Tables 3-5 ).
Tolerability and Safety
Dry mouth was the most common adverse event reported in each group; it was more common in the oxybutynin participants than in the tolterodine participants (29.7% vs 22.3%, respectively) ( Table 6 ). Although the difference between the groups was significant (P=.02), most dry mouth events were mild. The tolerability of this common adverse event is reflected by the small number of participants who cited dry mouth as a reason for discontinuation: 7 from the oxybutynin group and 4 from the tolterodine group. Other anticholinergic adverse events such as constipation, impaired urination-retention, or blurred vision occurred at similar frequencies in each group. Central nervous system (CNS) adverse effects such as dizziness, somnolence, depression, and confusion were infrequent and similar in magnitude for both groups. The frequency of other adverse events was low and did not differ by more than 2.5 percentage points between treatment groups. Overall, adverse events resulted in discontinuation of study medication by 20 participants receiving oxybutynin and 19 receiving tolterodine. No serious adverse events were attributed to either drug.
DISCUSSION
Oxybutynin and tolterodine are widely used for OAB. The availability of the 2 agents raises the issue of their relative merits. Past studies have compared results obtained with immediate-release formulations or with extended-release oxybutynin vs immediate-release tolterodine. [15] [16] [17] With the introduction and increasing use of extended-release formulations for both oxybutynin and tolterodine, the OPERA trial was designed as a comparative study to assess the 2 long-acting formulations.
Dose selection has important implications in that dose correlates with clinical effects. Studies of immediate-release tolterodine previously established that increasing the daily dose to a total of 8 mg/d produced dry mouth in as many as 56% of participants. More significantly, increases in postvoid residual volumes and urinary retention were noted and thought to be unacceptable. Because of these safety limitations, development of doses higher than 4 mg/d was discontinued. 18, 19 The subsequent development of extended-release tolterodine led to approval of 4 mg/d, with a provision for lowering the dose to 2 mg/d based on individual response and tolerability; however, limited efficacy data are available for 2 mg of tolterodine. 20 Thus, the OPERA trial used the maximum dose of extended-release tolterodine that is recognized as safe and effective by the FDA. For extended-release oxybutynin, results of previous studies, including the OBJECT study, 15 led to the selection of a dose of 10 mg/d for the OPERA study.
In the current study, the effect of 10 mg of extendedrelease oxybutynin was numerically greater than 4 mg of tolterodine at every efficacy assessment point for all primary and additional efficacy variables. Reductions in the weekly frequency of UUI (primary end point) and total incontinence episodes were similar for both groups and were not statistically significant. In contrast, extendedrelease oxybutynin at 10 mg/d proved to be more effective than extended-release tolterodine at 4 mg/d in reducing the weekly micturition frequency. Complete control of incontinence was reported by 23.0% of participants taking extended-release oxybutynin compared with 16.8% of patients taking extended-release tolterodine (P=.03), the difference representing a 37% advantage for extended-release oxybutynin compared with extended-release tolterodine. Efficacy comparisons must be balanced by an analysis of the comparative adverse event profiles. Anticholinergic drugs have a typical spectrum of adverse events. Dry mouth was the most common adverse event in both groups: 29.7% in the extended-release oxybutynin group vs 22.3% in the extended-release tolterodine group. Most episodes of dry mouth were rated mild, defined in the protocol as noticeable without influencing daily activities and usually would not need intervention. When the number of participants who did not report dry mouth is combined with the number of those who reported mild as the most severe dry mouth they experienced during the trial, 93% of oxybutynin participants and 95% of tolterodine participants did not experience dry mouth that would be considered clinically important. Few participants discontinued treatment because of dry mouth in either group (7 from the oxybutynin and 4 from the tolterodine group). The frequency of other typical anticholinergic adverse events such as blurred vision and urinary retention was less than 5% in each group and similar in magnitude for both groups.
Some authors have suggested that oxybutynin might cause more adverse events of the CNS than tolterodine because oxybutynin is more lipophilic and would therefore achieve a higher concentration in the cerebrospinal fluid. 21 In the absence of drug measurement in the cerebrospinal fluid or CNS tissue, this conjecture remains speculative. However, the current study provides a direct clinical comparison that shows CNS adverse effects such as dizziness, somnolence, insomnia, and depression were reported at rates between 1% and 4% for both drugs. Other CNS effects were reported by less than 1% of participants. Thus, actual clinical 9 (18.9) *Sample sizes at baseline and weeks 2, 4, 8, 12, and final week were 382, 380, 365, 346, 336, and 382, respectively, for oxybutynin and 393, 390, 383, 370, 355 , and 393, respectively, for tolterodine. †Wilcoxon rank sum test. ‡Negative numbers indicate an increase from baseline.
experience from both the OBJECT study and the OPERA study provides direct evidence that there is no clinically meaningful difference in the tolerability profile between extended-release oxybutynin at 10 mg/d and tolterodine in either the immediate-or extended-release formulations.
In the current study, the efficacy of extended-release oxybutynin at 10 mg/d was modestly greater than extended-release tolterodine at 4 mg/d. However, extendedrelease oxybutynin offers greater dosing flexibility to achieve the optimal balance between efficacy and tolerability because of the wide range of approved doses: from 5 to 30 mg/d. If patients whose initial daily dose of 10 mg of extended-release oxybutynin are not satisfied with their improvement, they can increase the daily dose to 15, 20, 25 , or even 30 mg, if needed.
Several articles have emphasized the effect of incontinence on an individual's quality of life. Embarrassment, frustration, anxiety, annoyance, depression, and fear of odor are common reactions to urinary incontinence and lead to various coping mechanisms, including using incontinence pads or garments, wearing dark clothing, carrying a change of clothing, reducing fluid intake, and limiting travel. 1 Incontinence has also been noted to negatively affect dating, sexual activity, feeling attractive, and selfesteem, more so in women younger than 70 years compared with older women. 22 Avoidance of sexual intimacy is reflected by the observation that, although the desired frequency of intercourse was similar between participants with and without incontinence, the actual frequency of intercourse was significantly less among participants with incontinence.
1 These findings support the contention that uncontrolled incontinence, especially the difficulty in predicting episodes of UUI, imposes considerable burden on individuals with OAB. For those who adopt disruptive mechanisms to cope with OAB, the ability to control incontinence has clear importance. The superiority of extendedrelease oxybutynin in controlling incontinence episodes is clearly important for individuals who want to optimize their chances of avoiding incontinence.
Potential issues could be raised about the representativeness of the OPERA study. First, the OPERA study enrolled only women and hence does not provide information about response in men. However, women constitute most of the individuals presenting for treatment of incontinence and have in fact predominated in prior studies. 9, [13] [14] [15] [16] [17] [18] Also, the OPERA study enrolled participants who had 21 to 60 UUI episodes per week, a degree of severity that provides a potentially greater challenge to control. Because of the focus on this population, the OPERA study does not provide direct comparison of extended-release formulations of oxybutynin and tolterodine in participants with fewer UUI episodes at baseline. If there were clinically significant differences in the tolerability of the 2 treatment regimens, this ambiguity might be worth more consideration. However, the similar tolerability of extended-release oxybutynin at 10 mg/d and extended-release tolterodine of 4 mg/d is compelling enough to consider differences in efficacy. Of note is the lack of a placebo comparator in the OPERA study. The trial was designed as a comparative study of 2 FDA-approved extended-release treatments of OAB. Although a "placebo effect" is a possible consequence in any drug study and efficacy of placebo has been described in a similar 12-week study of extended-release tolterodine, 23 efficacy of both agents over placebo is established. The inclusion of a placebo in the OPERA study would not have helped to answer the questions the study was designed to evaluate.
CONCLUSIONS
Participants who took extended-release oxybutynin had numerically superior outcomes at all visits for all end points, although not all differences were statistically significant. Reductions in weekly UUI and total incontinence episodes were similar with extended-release formulations of oxybutynin and tolterodine, but oxybutynin participants had significantly lower micturition frequency. Except for a higher incidence of dry mouth with oxybutynin, both drugs had comparable tolerability, including adverse events involving the CNS. The availability of these once-aday extended-release preparations of drugs for OAB, particularly the flexible-dosing capability of extended-release oxybutynin, provides treatment options for better control of OAB.
